Lexapro, Namenda Inventory Workdowns Cut Forest's Fourth Quarter Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Wholesale inventory levels of the antidepressant Lexapro fell from 21 days at the end of 2004 to 15 days as of March 31, Forest says. Total prescription volume of the Alzheimer's agent Namenda increased, but sales were similarly negatively impacted by inventory workdowns, the company says.
You may also be interested in...
Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.
Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.
Antidepressant Market Will Remain Flat In Face Of Adult Suicidality Concerns, Forest Says
The impact of media attention on the adult suicide issue will be “hard to predict,” President & COO Goodman says. Forest expects FDA action on a Namenda supplemental NDA for mild-to-moderate Alzheimer’s in the next few weeks.